Filtering by:
ImmunotherapyFDA Approves Keytruda (Pembrolizumab) for Head and Neck Cancer
The US Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a first-line treatment for people with advanced head and neck cancer.
FDA Approves Tecentriq (Atezolizumab) for Small Cell Lung Cancer
The US Food and Drug Administration (FDA) has approved the immunotherapy drug Tecentriq (atezolizumab) for the treatment of small cell lung cancer (SCLC).
FDA Approves Immunotherapy for Breast Cancer
The US Food and Drug Administration today approved the first immunotherapy treatment for breast cancer. It approved a combination of Tecentriq (atezolizumab) and Abraxane (nab-paclitaxel) for people with advanced triple negative breast cancer.
2018 in Review: New Cancer Drug Approvals
In 2018, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.
Study Supports Immunotherapy for Treating Triple-Negative Breast Cancer
A study by an international group of researchers has found for the first time that a combination of immunotherapy and chemotherapy can extend lives of women with triple-negative breast cancer.
FDA Approves Libtayo (Cemiplimab) for a Type of Skin Cancer
The US Food and Drug Administration (FDA) has approved Libtayo (cemiplimab) to treat people with advanced squamous cell carcinoma of the skin.
Nobel Prize Awarded to Cancer Immunotherapy Researchers
The 2018 Nobel Prize in Physiology or Medicine has been awarded jointly to two cancer immunotherapy researchers, James P. Allison, PhD, of The University of Texas MD Anderson Cancer Center, and Dr. Tasuku Honjo of Kyoto University in Japan.
FDA Approves Opdivo (Nivolumab) for Small Cell Lung Cancer
The US Food and Drug Administration had approved the immunotherapy drug Opdivo (nivolumab) to treat people with small cell lung cancer (SCLC).